BRCA2 and ovarian carcinoma: Then we sought to investigate whether combined anti-CD47 therapy and PARP inhibition will be more effective than monotherapy using two in-vivo xenograft models: (1) BRCA2 mutated PEO1 ovarian cancer cells implanted subcutaneously in NSG mice and (2) SKOV3 with BRCA1 knockdown (KD) implanted intraperitoneally in NOD/SCID mice.